Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

The thyroid hormone receptor-beta (THR-b) drug ALG-055009:

• Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects
• Demonstrated favorable PK with low variability
• Dose responsively lowered lipid levels in study subjects
• Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies
• Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent
• Has a favorable overall risk-benefit profile which supports conducting a 12-week Phase 2a study in NASH subjects

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11^th at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023. The clinical (#2900-A) and nonclinical (#2461-C) posters for these data can also be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com).

The clinical poster describes a Phase 1 study which evaluated 14 oral daily doses of up to 1.0 mg ALG-055009 solution formulation in hypercholesterolemic subjects. Important highlights include:

1. ALG-055009 was well tolerated with no safety signals identified
2. No clinical evidence of hyper- or hypo-thyroidism was observed
3. As expected for a thyromimetic, ALG-055009 dose responsively
   1. Increased sex hormone binding globulin levels
   2. Lowered lipids levels
4. ALG-055009 exposures increased in a dose proportional manner with low variability (geometric CV <30%) and a ~20 hour half-life that supports QD dosing
5. The planned Phase 2a gelcap formulation delivered exposures ~86% of the solution formulation and did not demonstrate a food effect
   

The nonclinical poster describes in vitro and in vivo studies which characterize the properties of ALG-055009. Important highlights include:

1. ALG-055009 is 5-47 times more potent than resmetirom and VK-2809 (parent)
2. ALG-055009 is more beta selective than resmetirom and VK-2809 (parent) in cell based assays
3. Lipid levels decreased in a dose responsive manner in in vivo models
4. In 13-week repeat dose toxicology studies, ALG-055009 was well tolerated with safety margins supporting dosing in the planned Phase 2a clinical study    

“We are excited to share at AASLD these favorable clinical and nonclinical data, which serve as the basis for advancing ALG-055009 into a Phase 2a study in NASH patients,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “This study, called the HEpatic fat Reduction with ALG-055009 in steatotic Liver Disease (HERALD) study, is on track to initiate dosing in Q1 2024 with topline data, including 12-week MRI-PDFF results, projected in Q4 2024.”